Document is current
Any future updates will be listed below
-
Authors
Guisado-Vasco, P. http://orcid.org/0000-0003-3019-4398
Carralón-González, M. M.
Aguareles-Gorines, J.
Martí-Ballesteros, E. M.
Sánchez-Manzano, M. D.
Carnevali-Ruiz, D.
García-Coca, M.
Barrena-Puertas, R.
de Viedma, R. García
Luque-Pinilla, J. M.
Sotres-Fernandez, G.
Fernández-Sousa, J. M.
Luepke-Estefan, X. E.
López-Martín, J. A.
Jimeno, J. M.
-
Funding
Funding for this research was provided by:
Pharma Mar SA
- License Information
-
More Information
Article History
Received: 20 November 2021
Accepted: 7 December 2021
First Online: 10 January 2022
Declarations
:
: We obtained institutional written consent from the patient for publication of his data under anonymized format.
: We obtained the patient’s signed written consent form for the publication of the current case report.
: José M. Fernández-Sousa is President and Founder of Pharma Mar, S.A. (Madrid, Spain). José M. Jimeno holds stocks of Pangae Oncology, has a non-remunerated role in the Scientific Advisory Board, and holds stocks of Phosplatin Therapeutics; and is a full-time employee of Pharma Mar, S.A. (Madrid, Spain). José A. López-Martín is an employee and shareholder of Pharma Mar, S.A (Madrid, Spain), and a co-inventor of a patent for Plitidepsin (WO2008135793A1). Xarles Erik Luepke Estefan is an employee and shareholder of Pharma Mar, S.A (Madrid, Spain). All remaining authors have declared no conflicts of interest.
